Clementia Pharmaceuticals Inc. (CMTA) PT Raised to $27 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CMTA Hot Sheet
Price: $26.35 --0%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz raised the price target on Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) to $27.00 (from $26.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Revolve Group (RVLV) PT Lowered to $26 at Piper Sandler
- Xometry Inc (XMTR) PT Raised to $114 at Cantor Fitzgerald
- Modine Manufacturing (MOD) PT Lowered at KeyBanc on 'Margin Headwinds'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
